Richard G Bach
Overview
Explore the profile of Richard G Bach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
1719
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ostrominski J, Claggett B, Jerosch-Herold M, Raja A, Day S, Russell M, et al.
JAMA Cardiol
. 2025 Mar;
PMID: 40042824
Importance: Valsartan has been shown to attenuate phenotypic progression among individuals with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Myocardial tissue characterization by cardiac magnetic resonance (CMR) imaging may enhance mechanistic insights,...
2.
Wang A, Lakdawala N, Abraham T, Nilles E, Wojdyla D, Owens A, et al.
J Card Fail
. 2024 Dec;
PMID: 39653325
Background And Aims: In patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM), it is unclear if response to cardiac myosin inhibition varies with older age or a longer duration of diagnosis....
3.
Arnold S, Gosch K, Dolan C, Fine J, Masri A, Saberi S, et al.
Circulation
. 2024 Nov;
150(19):1560-1562.
PMID: 39495835
No abstract available.
4.
Ireland C, Burstein D, Day S, Raja A, Russell M, Zahka K, et al.
Circ Heart Fail
. 2024 Aug;
17(8):e011663.
PMID: 39087355
Background: The health-related quality of life (HRQOL) and cardiopulmonary exercise testing (CPET) performance of individuals with subclinical and early stage hypertrophic cardiomyopathy (HCM) have not been systematically studied. Improved understanding...
5.
Husaini M, Bach R, Cresci S
J Am Coll Cardiol
. 2024 Jul;
84(6):602-606.
PMID: 38970597
Rest imaging in hypertrophic cardiomyopathy may underestimate or miss left ventricular outflow tract obstruction, leading to suboptimal management decisions that negatively affect symptomatic patients. The 2024 hypertrophic cardiomyopathy guidelines describe...
6.
Cresci S, Bach R, Saberi S, Owens A, Spertus J, Hegde S, et al.
Circulation
. 2023 Nov;
149(7):498-509.
PMID: 37961906
Background: Compared with men, women with hypertrophic cardiomyopathy (HCM) have a higher incidence of heart failure and worse outcomes. We investigated baseline clinical and echocardiographic characteristics and response to mavacamten...
7.
Bach R
Ann Intern Med
. 2023 Nov;
176(11):JC122.
PMID: 37931266
Arrhythmia and death following percutaneous revascularization in ischemic left ventricular dysfunction: prespecified analyses from the REVIVED-BCIS2 trial. Circulation. 2023;148:862-871. 37555345.
8.
9.
Vissing C, Raja A, Day S, Russell M, Zahka K, Lever H, et al.
JAMA Cardiol
. 2023 Sep;
8(11):1083-1088.
PMID: 37672268
Importance: Valsartan has shown promise in attenuating cardiac remodeling in patients with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Genetic testing can identify individuals at risk of HCM in a subclinical stage...
10.
Zajarias A, Bach R
Ann Intern Med
. 2023 Jun;
176(6):JC67.
PMID: 37276601
Sorajja P, Whisenant B, Hamid N, et al; TRILUMINATE Pivotal Investigators. N Engl J Med. 4 Mar 2023. [Epub ahead of print]. 36876753.